PBMs made billions marking up specialty drugs by more than 1,000 percent: FTC
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying the major industry middlemen generate billions in revenue through
Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
FTC finds middlemen inflate specialty generic drug prices by billions of dollars
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs between 2017 and 2022,
Top three insurers reaped $7.3 billion through their drug middlemen’s markups, FTC says
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from ‘excess’ prescription price hikes of 1,000% or more.
FTC takes fresh swipe at drug middlemen, says some prices marked up over 1,000%
The drug middlemen known as pharmacy-benefit managers took another body blow from regulators on Tuesday, as they were criticized for charging way more for some “critical” prescription drugs than it cost them.
FTC says ‘Big 3 PBMs’ marked up generic drugs by thousands of percent
The Federal Trade Commission published a second interim staff report on the prescription drug middleman industry, which it says focuses on
PBMs Generated Billions in Drug Markups, FTC Says
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with, the FTC said in a new report.
PBMs made more than $7B marking up specialty generics: FTC
The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty generic drugs for cancer, HIV and other conditions, the Federal Trade Commission charged on Tuesday.
Drugmakers hiked prices for hundreds of drugs in early January
January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including ...
Hosted on MSN9h
'Raking in billions': Report shows Drug middlemen jack up prices by nearly 8,000%
The U.S. Federal Trade Commission on Tuesday published the second part of its investigation into how prescription drug ...
Forbes28d
How PBM Reform Could Help Walgreens And Other Retail Pharmacies
Included in a so-called “continuing resolution” before Congress is a “provision that would require PBMs to reimburse pharmacies at (National Average Drug Acquisition Cost) plus the state’s ...
Crain's Chicago Business5d
More bills targeting pharma middlemen pop up in Springfield
consumer or employer and forbid a PBM from paying a reimbursement less than the national average drug acquisition cost, plus a professional dispensing fee. The legislation mandates that contracts ...
Drug Store News26d
Pharmacy groups to “key vote” continuing resolution with PBM reforms
Ensuring fair and adequate Medicaid managed care pharmacy reimbursement from PBMs to cover the cost to acquire and dispense prescription drugs. Requiring National Average Drug Acquisition Cost ...
Forbes1mon
Does PBM Expansion Into Drug Manufacturing Benefit Patients Or Risk Further Anti-Competitive Behaviors?
are often paid 20- to 40-times the National Average Drug Acquisition Cost, and significantly more than unaffiliated pharmacies. This preferential treatment harms independent pharmacies and ...
Yahoo Finance28d
NACDS Lauds Congress for CR Negotiations, Declares "Key Votes" in House and Senate to Secure PBM Reforms Crucial for Americans and Their Pharmacies
Ensuring fair and adequate Medicaid managed care pharmacy reimbursement from PBMs to cover the cost to acquire and dispense prescription drugs. - Requiring National Average Drug Acquisition Cost ...
Investing1d
FTC report shows major PBMs mark up specialty drugs significantly
Investing.com -- The Federal Trade Commission (FTC) has released a report showing that the three largest pharmacy benefit managers (PBMs) in the industry have significantly marked up prices on ...
Medscape3d
Drugs for STD management in developing countries: choice, procurement, cost, and financing.
METHODS: National STD guidelines, purchasing mechanisms, and drug acquisition costs from 15 countries were compiled, using information from ministries of health and European Commissions ...
FTC Release: FTC Releases Second Interim Staff Report on Prescription Drug Middlemen
Report finds PBMs charge significant markups for cancer, HIV, and other critical specialty generic drugs The Federal Trade Commission today published a second interim staff report on the prescription ...